Longer disease duration doesn’t seem to impact teprotumumab response in TED

Data from the OPTIC phase 3, 24-week randomized, double-masked, placebo-controlled treatment trial was used to assess long-term proptosis response in patients who received teprotumumab.

The majority of patients on teprotumumab who responded to treatment (≥ 2 mm improvement in proptosis) maintained their response at week 72. Patients in the OPTIC trial who did not qualify as proptosis responders at Week 24 or were responders at Week 24 but flared during the follow-up period, were evaluated in OPTIC-X.

A total of 61% of patients who received placebo during the OPTIC trial and then enrolled in OPTIC-X and received teprotumumab were considered diplopia responders (≥1 grade improvement) at Week 24. On average, these patients had a TED diagnosis for 1-year before treatment compared with 6 months from diagnosis to treatment in the treatment group in the OPTIC trial.

Reference
Douglas RS, et al. Long-Term Assessment of Proptosis and Diplopia From the OPTIC Trial of Teprotumumab in Thyroid Eye Disease. Presented at: AAO 2020 Virtual.